Literature DB >> 20689417

Cardiovascular complications of AIDS.

John Lekakis1, Ignatios Ikonomidis.   

Abstract

PURPOSE OF REVIEW: The purpose of the present review article is to present the recent data on the cardiovascular complications in patients infected with HIV as well as the preventive strategies to reduce cardiovascular disease in those patients. RECENT
FINDINGS: Individuals infected with HIV frequently demonstrate a metabolic syndrome associated with atherosclerosis and cardiovascular disease. Extensive functional and structural arterial wall changes have been observed in these individuals. It is documented that these vascular changes are closely related to highly active antiretroviral treatment-induced metabolic disorders as well as characteristics of the HIV infection itself. Intensive treatment of vascular dysfunction might be helpful in preventing or retarding the atherosclerotic process in HIV patients.
SUMMARY: Marked changes in arterial function and structure are observed in HIV patients leading to increased cardiovascular morbidity and mortality. Early antiretroviral therapy and aggressive treatment of cardiovascular risk factors might be helpful.

Entities:  

Mesh:

Year:  2010        PMID: 20689417     DOI: 10.1097/MCC.0b013e32833e10a9

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  13 in total

1.  Myocardial deformation imaging unmasks subtle left ventricular systolic dysfunction in asymptomatic and treatment-naïve HIV patients.

Authors:  Apostolos Karavidas; George Xylomenos; Vassiliki Matzaraki; Nikolaos Papoutsidakis; Georgios Leventopoulos; Dimitrios Farmakis; George Lazaros; Anastasia Perpinia; Sophia Arapi; Nikolaos Paisios; John Parissis; Vlasios Pyrgakis; Panagiotis Gargalianos
Journal:  Clin Res Cardiol       Date:  2015-05-15       Impact factor: 5.460

Review 2.  Novel cell and gene therapies for HIV.

Authors:  James A Hoxie; Carl H June
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

Review 3.  Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

Review 4.  Plasmacytoid dendritic cells in HIV infection.

Authors:  Meagan O'Brien; Olivier Manches; Nina Bhardwaj
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

5.  The Evaluation of Carotid Atherosclerosis in Patients with the HIV-1 Infection: The Role of the Antiretroviral Therapy.

Authors:  Suparna P N; Basavaprabhu Achappa; Unnikrishnan B; Deepak Madi; Mukta N Chowta; John T Ramapuram; Satish Rao; Soundarya Mahalingam
Journal:  J Clin Diagn Res       Date:  2013-02-01

6.  Adverse host factors exacerbate occult HIV-associated nephropathy.

Authors:  Dileep Kumar; Divya Salhan; Sandeep Magoon; Deepti D Torri; Swapna Sayeneni; Ankita Sagar; Anshu Bandhlish; Ashwani Malhotra; Praveen N Chander; Pravin C Singhal
Journal:  Am J Pathol       Date:  2011-08-24       Impact factor: 4.307

7.  Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation.

Authors:  De-xiu Bu; Margarite Tarrio; Elena Maganto-Garcia; George Stavrakis; Goro Tajima; James Lederer; Petr Jarolim; Gordon J Freeman; Arlene H Sharpe; Andrew H Lichtman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-03-10       Impact factor: 8.311

8.  Colorectal cancer screening in human immunodeficiency virus population: Are they at average risk?

Authors:  Suresh Kumar Nayudu; Bhavna Balar
Journal:  World J Gastrointest Oncol       Date:  2012-12-15

Review 9.  Dendritic cell dysregulation during HIV-1 infection.

Authors:  Elizabeth Miller; Nina Bhardwaj
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

10.  Evaluation of right ventricular function by Doppler tissue imaging of the tricuspid annulus in patients with acquired immune deficiency syndrome.

Authors:  Haohui Zhu; Jianjun Yuan; Changhua Wei; Jiyun Chen; Yisa Wang
Journal:  Exp Ther Med       Date:  2014-01-08       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.